Merck & Co. Inc., known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for WELIREG® (belzutifan). This marks a significant development as WELIREG becomes the only approved treatment in the United States for adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). These are rare tumors that originate from the same tissue, but differ in their location of formation. The approval is based on data from the LITESPARK-015 clinical trial, highlighting Merck's commitment to providing innovative therapies for patients with rare diseases.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。